ranging from 150 to 360 days). Two patients had lesions affecting the upper third of the face, and symmetry was achieved after unilateral treatment of the frontalis muscle. Three patients had injury in the middle third; their treatment depended of analysis of the deviation vectors when smiling and frowning, as to decide which muscle groups should be treated (vertical: upper lip lifter muscles; upper oblique: lifters of the angle of the mouth muscles; and horizontal: risorius muscle). Four patients were affected in the lower third (inferior deviation vectors) and were treated with 2 points to paralyze the lower lip depressor muscles. Correction of asymmetry was achieved in all cases. Recovery from the nerve injury and BTXA application occurred symmetrically in both sides of the face in the following months. All patients with early onset of BTXA therapy (<30 days) had complete recovery of facial symmetry with a single application, evidence of neuropraxis. Patients with lesions of the upper third, those with late onset of BTXA treatment (>30 days), and those with >1 affected nervous branch presented definitive lesion, with partial recovery or improvement, and needed BTXA treatment every 6 months.
CONCLUSION:
Most facial nerve injuries post-facelifts presented favorable evolution for spontaneous resolution, except in the upper third of the face and in case of late lesions. Symmetry was achieved in all cases with low doses of BTXA in the suggested protocol points, avoiding an unhappy asymmetric patient in the following months.
INTRODUCTION AND AIMS:
The Earfold implant system, made from a nickel-titanium alloy, is deployed and bends auricular cartilage to address an underdeveloped antihelical fold. In 2018, Kang et al 1 (the device inventor) published a series of 403 patients treated with the Earfold device, showing acceptable safety outcomes. The aim of this study is to report the early results and technical tips from 2 UK plastic surgeons implementing the Earfold system into their esthetic practice.
MATERIALS AND METHODS:
A retrospective review of all patients who received Earfold implants between February 2017 and August 2018 was undertaken. This was a consecutive series carried out in 2 separate UK clinics. Demographics, clinical outcomes, complications, and followup data were collected from electronic records.
KEY RESULTS:
A total of 79 implants were used in 36 patients, with 82% (n = 31) placed bilaterally. Mean age was 35 years (56% female). Overall complication rate leading to implant removal was 22% (n = 8), compared to 10% reported by Kang et al. 1 Indication for implant removal included implant visibility (n = 2), chronic pain (n = 2), undercorrection (n = 1), and erosion (n = 3). Three patients who had implants removed previously had an otoplasty procedure, and 1 was a recent ex-smoker. Eightyeight percent (7/8) of complications occurred in the first 50% of Earfold cases performed. Average follow-up time from surgery was 19 weeks.
CONCLUSIONS:
The Earfold system gives reproducible results that can be visualized by patients before surgery and is becoming increasingly popular. Our results indicate higher revision rates than those reported by Kang et al 1 but similar to their initial published results in 2016. 2 The trend seems to support a learning curve associated with Earfold, and we advise careful patient selection, in particular a history of previous otoplasty, when starting to use the device. is known to prevent fibroblast proliferation and expression of transforming growth factor-β1. It also induces temporary muscle paralysis and decreases tension vectors. Fibroblasts induce scar contracture and hypertrophy by producing collagen fibers in wound healing processes. In theory, botulinum toxin can play a vital role in scar prevention by reducing contracture and relaxing the adjacent muscles. Several studies have suggested the possibility of injecting botulinum toxin into nearby musculature around the traumatic or incisional wounds. However, sound clinical evidence has been missing. The aim of this study is to investigate the subjective and objective evidence of the effect that botulinum toxin has on scar formation in human. This is a prospective, split-scar, double-blinded, randomized controlled study. From February 2012 to December 2015, patients who presented forehead lacerations were recruited from the emergency room. Forty-five patients with forehead laceration were enrolled in this study and randomized into 2 groups with or without injection of BoNTA. When the patients presented to the clinic to remove the stitches, BoNTA was injected to the BoNTA group with 24 patients and saline was injected to the control group with 21 patients. The BoNTA was injected on dermal layer with 5 units/cm within a 0.5 cm distance on BoNTA group. Placebo drug was prepared as a vial containing 0.9% saline which is similar to BoNTA. After that, follow-up was done in 1, 3, and 6 months. The scars were analyzed with the Patient and Observer Scar Assessment Scale, Stony Brook Scar Evaluation Scales, and Visual Analog Scale and analyzed with independent t test, along with clinical photographs, cutometer, and biopsies. There were 21 patients in the control group and 24 patients in the BoNTA group. There were no significant adverse events in all patients. In all scar scales, the scores changed into favorable direction in both groups and the changes were larger in BoNTA group compared with the control group. However, when the amount of changes of the scar scales was investigated, there were more favorable changes in BoNTA group, which was proved statistically in Stony Brook Scar Evaluation Scales (P = 0.047) and Visual Analogue Scale (P = 0.046). Even without statistical significance, there were more favorable changes in BoNTA group in Patient Scar Assessment Scale (P = 0.110) and Observer Scar Assessment Scale (P = 0.169). Skin biopsy showed less collagen deposition on dermal layer in BoNTA group. In hematoxylin and eosin stain and Masson-trichrome stain, there was a denser deposition of collagen fibers of the specimen belonging to the control group compared to the BoNTA group. Based on the findings above, BoNTA can improve scar properties in various aspects, especially in decreasing collagen synthesis. The gross findings also showed favorable changes. This study provides useful indication of application of BoNTA in scar prevention with promising results.
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INTRODUCTION: Pedal fat grafting has been shown to improve pain and functional impairment from forefoot fat pad atrophy. We aim to determine whether patient demographics and foot characteristics play a role in the level of impact that is achieved following surgery.
METHODS:
We performed a retrospective review of patients who received forefoot autologous fat injections for the treatment of pedal fat pad atrophy. Patient improvement of pain and functional impairment was measured using the Manchester Foot Pain and Disability Index. One-way analysis of variance statistical analyses were used to evaluate correlation between patient characteristics and an improvement in survey scores assessing pain and functional impairment from the time of surgery to 6 months, to 12 months, and from 6 to 12 months. Patient characteristics examined include gender, age, body mass index (BMI), unilateral or bilateral injections, a flexible or rigid foot arch, previous foot deformity or surgery, and the presence of callus.
RESULTS:
Forty-four patients received fat injections into the ball of their foot. Seventy-three percent of them were women; their mean age was 61 years old, and mean BMI was 26.6 kg/m 2 . Seventy-five percentage had injections performed bilaterally. Forty-one percentage had a flexible arch, 73% had a history of pedal deformity or surgery, and 43% had callus. Significant findings included a correlation between female gender and an improvement in pain from the time of surgery to 12 months later (P = 0.02), a correlation between unilateral injections and an improvement in pain from the time of surgery to 6 months later (P = 0.03),
